ArticleCancer research communications2024
Tumor NOS2 and COX2 Spatial Juxtaposition with CD8+ T Cells Promote Metastatic and Cancer Stem Cell Niches that Lead to Poor Outcome in ER- Breast Cancer.
Abstract read
In one paragraph
Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nitric oxide-driven Warburg reprogramming at the NOS2-COX2 axis: An integrative engine of cancer hallmarks.Redox biology · 2026Review
- NOS2 and COX2 impact the spatial landscape of CD8Redox biology · 2026Review
- Endogenous modulators in lung cancer.World journal of clinical cases · 2025Article
- Elevated tumor NOS2/COX2 promotes immunosuppressive phenotypes associated with poor survival in ER- breast cancer.JCI insight · 2025Article
- Inducible nitric oxide synthase (iNOS): More than an inducible enzyme? Rethinking the classification of NOS isoforms.Pharmacological research · 2025Review
- The dual role of autophagy in cancer stem cells: implications for tumor progression and therapy resistance.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Lisa A Ridnour *Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0001-9446-8349
William F Heinz *Optical Microscopy and Analysis Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-6194-0536
Robert Y S Cheng *Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0003-0287-6439
Adelaide L Wink *Optical Microscopy and Analysis Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0009-0006-7904-2060
Noemi KedeiCollaborative Protein Technology Resource (CPTR) Nanoscale Protein Analysis, Office of Science and Technology Resources, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-6625-6119
Milind PoreImaging Mass Cytometry, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0001-6513-653X
Fatima ImtiazCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0009-0009-8511-3883
Elise L FeminoCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0001-9490-1093
Ana L GonzalezCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0009-0003-9125-3758
Leandro L CoutinhoCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-0989-6144
Rebecca L MoffatOptical Microscopy and Analysis Laboratory, Office of Science and Technology Resources, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0009-0000-2675-8707
Donna ButcherMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland.ORCID 0000-0002-2065-8067
Elijah F EdmondsonMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland.ORCID 0000-0002-6106-3705
Xiaoxian LiDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia.ORCID 0000-0002-0995-1721
Maria Cristina RangelCenter for Translational Research in Oncology, ICESP/HC, Faculdade de Medicina da Universidade de São Paulo and Comprehensive Center for Precision Oncology, Universidade de São Paulo, São Paulo, Brazil.ORCID 0000-0002-8002-9617
Robert J KindersDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-5310-3367
Jens RittscherInstitute of Biomedical Engineering, Big Data Institute, Ludwig Oxford Branch, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-8528-8298
Stanley LipkowitzWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-6103-2255
Stephen T C WongHouston Methodist Neal Cancer Center, Weill Cornell Medical College, Houston Methodist Hospital, Houston, Texas.ORCID 0000-0001-9188-6502
Stephen K AndersonCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-7856-4266
Daniel W McVicarCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-1112-5111
Sharon A GlynnDiscipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland.ORCID 0000-0003-1459-2580
Timothy R BilliarDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-2949-0811
Jenny C ChangHouston Methodist Neal Cancer Center, Weill Cornell Medical College, Houston Methodist Hospital, Houston, Texas.ORCID 0000-0002-0890-9302
Stephen M HewittLaboratory of Pathology Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-8283-1788
Stefan AmbsLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-7651-9309
Stephen J LockettOptical Microscopy and Analysis Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-2010-9914
David A WinkCancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.ORCID 0000-0002-5652-7480
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6MTransport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, RONGFU · 2016 to 2020
$9.3MSpatiotemporal modeling of cancer-niche interactions in breast cancer bone metastasisU01CA253553 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC, ZHANG, XIANG · 2020 to 2024
$3.0MSystematic identification of astrocyte-tumor crosstalk regulating brain metastatic tumorsR01CA238727 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC, ZHAO, HONG · 2020 to 2024
$2.6MSCIENTIFIC, OPERATIONS, AND ADMINISTRATIVE RESOURCES (SOAR) TO NIH.75N95021D00012 · NIDA · KELLY SERVICES, INC. · PI SPROSE, SARA · 2021 to 2021
$57kNCI NIH HHS 75N91019D00024NCI NIH HHS R01 CA238727NCI NIH HHS U01 CA253553NCI NIH HHS U54 CA210181NIDA NIH HHS 75N95021D00012
Abstract
significanceThis work identifies CD8-NOS2+COX2+ and CD8-NOS2-COX2+ unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8+ T cells predictive of clinical outcome and can be targeted with clinically available NOS inhibitors and NSAIDs.
Indexed as
Breast NeoplasmsCD8-Positive T-LymphocytesCyclooxygenase 2Neoplastic Stem CellsNitric Oxide Synthase Type IIAnimalsFemaleHumansMiceNeoplasm MetastasisReceptors, EstrogenStem Cell NicheTumor MicroenvironmentCyclooxygenase 2Nitric Oxide Synthase Type IINOS2 protein, humanPTGS2 protein, humanReceptors, Estrogen
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.